This item is part of Stockwatch's value added news feed and is only available to Stockwatch subscribers.Here is a sample of this item:Teva Introduces Fexofenadine HCl and Pseudoephedrine HCl Extended-Release Tablets; An Alternative to Allegra-D® 12 Hour Tablets 2009-11-03 15:35 ET - News Release
JERUSALEM -- (Business Wire)
Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today the
commercial launch of Fexofenadine Hydrochloride 60 mg and
Pseudoephedrine Hydrochloride 120 mg Extended-Release Tablets, the same
as the sanofi-aventis U.S. allergy treatment Allegra-D® 12 Hour
(fexofenadine HCl 60 mg and pseudoephedrine HCl 120 mg) Extended-Release
Tablets. Teva's product is an alternative to the brand product, which
had annual sales of approximately $293 million in the United States for
the twelve months that ended June 30, 2009, based on IMS sales data.
As the first company to file an ANDA containing a paragraph IV
certification for this product, Teva has been awarded a 180-day period
of marketing exclusivity in the U.S.
Teva is distributing the product, under a license agreement entered into
between Teva's subsidiary Barr Pharmaceuticals, Inc. and sanofi-aventis
U.S. Allegra-D is a registered trademark of sanofi-aventis U.S.
The remainder is available to Stockwatch subscribers.
If you would like to give the Stockwatch system a try,
click here for a free 30 day trial subscription. |
Top
Print this Page